Article Text

Download PDFPDF
Dapagliflozin no longer licensed for type 1 diabetes

Abstract

  • health care quality
  • access
  • and evaluation
  • drug-related side effects and adverse reactions

Statistics from Altmetric.com

Footnotes

  • Overeview of Medicines and Healthcare products Regulatory Agency. Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus. Drug Safety Update 2021;15:3.

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.